A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.

Background: Typhoid fever is a serious bacterial infection caused by Salmonella Typhi, with a significant burden in low- and middle-income countries, particularly in Sub-Saharan Africa and South/Southeast Asia. To mitigate its spread, the World Health Organization (WHO) advocates for typhoid vaccina...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Subhash Thuluva, Ramesh V. Matur, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Chirag Dhar, Raju Esanakarra, Savita Verma, Manish Narang, Madhukar Pandey
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-08-01
Schriftenreihe:	Vaccine: X
Schlagworte:	Typhoid Typhoid conjugate vaccine (TCV) Salmonella Typhi Immunization
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2590136225000634
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!